ClinicalTrials.gg
CompletedNCT01134705Updated May 23, 2012Results posted

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

A Phase 3 interventional study of Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol and Placebo Nasal Aerosol in Rhinitis, Allergic, Perennial, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 35 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-05-23.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
474
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Rhinitis, Allergic, Perennial with a site in United States — none open to participants now, 1 under way, 1 of them phase 3. Rhinitis, Allergic, Perennial · United States.

Enrollment
18th of 57
474 · median 301
Started
2010
with 4 others
Phase 3
33 of 60
none open now
Registered
43rd of 60
by date
Lead sponsor
4 of 60
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, this one is the 18th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2010, is one of 33 in phase 3, and was the 43rd registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

None of the 60 studies in Rhinitis, Allergic, Perennial with a site in United States is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 60 studies in Rhinitis, Allergic, Perennial with a site in United States as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.

03

Conditions studied

  • Rhinitis, Allergic, Perennial
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of perennial allergic rhinitis
  • A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test.
  • Minimum subject-reported reflective total nasal symptom score (rTNSS) of at least 6 (out of a possible 12)
  • Other criteria apply

Exclusion criteria

Exclusion Criteria:

  • History of physical findings of nasal pathology (within 60 days prior to screening visit)
  • Participation in any drug study 30 days preceding screening visit
  • History of respiratory infection/disorder with 14 days preceding screening visit or during the run-in period
  • Use of any prohibited concomitant medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
474 participants (actual)

Study arms

  • Experimental
    BDP HFA 320 µg/day

    During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.

    Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol

  • Placebo comparator
    Placebo

    During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.

    Drug: Placebo Nasal Aerosol

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

    Time frame: Baseline (Days -3 to 0) and Days 1-43 (6-week Treatment Period)

Secondary outcomes

  1. Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Six-week Treatment Period

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to assessment twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptoms, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

    Time frame: Baseline (Days -3 to 0) and Days 1-43 (6-week Treatment Period)

  2. Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

    The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates improvement.

    Time frame: Baseline and Week 6

07

Results

Posted May 23, 2012

Participant flow

A total of 675 patients were screened and 574 patients were enrolled in the study and participated in the Run-in Period. Of the 574 enrolled patients, 474 were randomized to study treatment.

Participant flow — Overall Study
MilestoneBDP HFA 320 µg/DayPlacebo
Started236238
Intent to treat population232234
Completed221216
Not completed1522
Withdrew: Adverse event17
Withdrew: Withdrawal by subject66
Withdrew: Pregnancy10
Withdrew: Lost to follow-up52
Withdrew: Protocol violation11
Withdrew: Other16

Outcome measures

PrimaryChange From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

Time frame:
Baseline (Days -3 to 0) and Days 1-43 (6-week Treatment Period)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period-2.5 ± 0.14-1.6 ± 0.14
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · Repeated measures Analysis of covariance · p = <0.001 (A priori threshold for statistical significance is p\<0.05) · Ls mean difference: -0.84 · 95% CI -1.2 to -0.5The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Six-week Treatment Period

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to assessment twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptoms, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

Time frame:
Baseline (Days -3 to 0) and Days 1-43 (6-week Treatment Period)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Six-week Treatment Period
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Six-week Treatment Period-2.1 ± 0.13-1.4 ± 0.13
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · Repeated measures ANCOVA · p = <0.001 (A priori threshold for statistical significance is p\<0.05) · Ls mean difference: -0.78 · 95% CI -1.1 to -0.4The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates improvement.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)-1.5 ± 0.14-0.9 ± 0.14
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = 0.001 (A priori threshold for statistical significance is p\<0.05) · Ls mean difference: -0.58 · 95% CI -0.9 to -0.2ANCOVA with treatment, baseline and center in the model.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDP HFA 320 µg/Day—1/236 (0.4%)14/236 (5.9%)
Placebo—0/238 (0%)12/238 (5%)
Most frequent serious events
Most frequent serious events
EventBDP HFA 320 µg/DayPlacebo
ArrhythmiaCardiac disorders1/2360/238
Most frequent other events
Most frequent other events
EventBDP HFA 320 µg/DayPlacebo
Nasal discomfortRespiratory, thoracic and mediastinal disorders14/23612/238

Baseline characteristics

Age Continuous
Age Continuous(years)BDP HFA 320 µg/DayPlaceboTotal
Mean36.8 ± 14.537.2 ± 13.737.0 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)BDP HFA 320 µg/DayPlaceboTotal
Female158161319
Male7473147
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 320 µg/DayPlaceboTotal
White186185371
Black or African American404080
Asian6511
American Indian or Alaskan Native123
Other167
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 320 µg/DayPlaceboTotal
Hispanic or Latino263056
Not Hispanic or Latino206204410
Region of Enrollment
Region of Enrollment(participants)BDP HFA 320 µg/DayPlaceboTotal
United States232234466
08

Study locations

35 sites
  • Teva Clinical Study Site
    Los Angeles, California 90025, United States
  • Teva Clinical Study Site
    Mission Viejo, California 92691, United States
  • Teva Clinical Study Site
    San Diego, California 92123, United States
  • Teva Clinical Study Site
    San Jose, California 95117, United States
  • Teva Clinical Study Site
    Miami, Florida 33173, United States
  • Teva Clinical Study Site
    Tallahassee, Florida 32308, United States
  • Teva Clinical Study Site
    Lilburn, Georgia 30047, United States
  • Teva Clinical Study Site
    Indianapolis, Indiana 46208, United States
  • Teva Clinical Study Site
    Bangor, Maine 04401, United States
  • Teva Clinical Study Site
    Bethesda, Maryland 20814, United States
  • Teva Clinical Study Site
    Rolla, Missouri 65401, United States
  • Teva Clinical Study Site
    St. Louis, Missouri 63141, United States
  • Teva Clinical Study Site
    Brick, New Jersey 08724, United States
  • Teva Clinical Study Site
    Raleigh, North Carolina 27607, United States
  • Teva Clinical Study Site
    Winston Salem, North Carolina 27103, United States
  • Teva Clinical Study Site
    Canton, Ohio 44718, United States
  • Teva Clinical Study Site
    Medford, Oregon 97504, United States
  • Teva Clinical Study Site
    Portland, Oregon 97213, United States
  • Teva Clinical Study Site
    Blue Bell, Pennsylvania 19422, United States
  • Teva Clinical Study Site
    Upland, Pennsylvania 19013, United States
  • Teva Clinical Study Site
    Providence, Rhode Island 02906, United States
  • Teva Clinical Study Site
    Charleston, South Carolina 29407, United States
  • Teva Clinical Study Site
    Spartanburg, South Carolina 29303, United States
  • Teva Clinical Study Site
    Austin, Texas 78731, United States
  • Teva Clinical Study Site
    Dallas, Texas 75230, United States
  • Teva Clinical Study Site
    Dallas, Texas 75231, United States
  • Teva Clinical Study Site
    Ft. Worth, Texas 76132, United States
  • Teva Clinical Study Site
    Katy, Texas 77450, United States
  • Teva Clinical Study Site
    New Braunfels, Texas 78130, United States
  • Teva Clinical Study Site
    San Antonio, Texas 78229, United States
  • Teva Clinical Study Site
    San Antonio, Texas 78829, United States
  • Teva Clinical Study Site
    Waco, Texas 76712, United States
  • Teva Clinical Study Site
    Newport News, Virginia 23606, United States
  • Teva Clinical Study Site
    Richmond, Virginia 23233, United States
  • Teva Clinical Study Site
    Bellevue, Washington 68123, United States
09

References and documents

Publications

  • Meltzer EO, Jacobs RL, LaForce CF, Dorinsky PM, Kelley L, Dunbar SA, Tantry SK (2011). BDP HFA Nasal Aerosol 320 µg Once Daily Is Safe and Effective in the Treatment of Nasal Symptoms Associated With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol. 107(11):A118.
  • Meltzer EO, Jacobs RL, LaForce CF, Dorinsky PM, Kelley L, Dunbar SA, Tantry SK. . BDP HFA Nasal Aerosol 320 µg Once Daily Is Safe and Effective in the Treatment of Nasal Symptoms Associated With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol (Supplement); 107(11):A118 - Poster presentation.
  • Carr W, Meltzer EO, Finn A, Dorinsky PM, Kelley L, Dunbar SA, Tantry SK. Effective nasal symptom relief and improvement in health-related quality of life in subjects with perennial allergic rhinitis following 6-week
  • Meltzer EO, Korenblat PE, Lanier BQ, Kelley L, Tantry SK. Beclomethasone dipropionate nasal aerosol with an integrated dose counter: functionality and performance. Allergy Asthma Proc. 2013 Nov-Dec;34(6):534-41. doi: 10.2500/aap.2013.34.3707. PubMed 24169062 ↗
  • Nayak AS, Atiee GJ, Dige E, Maloney J, Nolte H. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy Asthma Proc. 2012 Sep-Oct;33(5):404-10. doi: 10.2500/aap.2012.33.3605. Erratum In: Allergy Asthma Proc. 2012 Nov-Dec;33(6):499. PubMed 23026182 ↗
  • Meltzer EO, Jacobs RL, LaForce CF, Kelley CL, Dunbar SA, Tantry SK. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc. 2012 May-Jun;33(3):249-57. doi: 10.2500/aap.2012.33.3571. PubMed 22737708 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 7 months after primary completion. A results delay was requested in Aug 2011.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2010
First posted
Jun 2, 2010
Start
May 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results delay requested
Aug 25, 2011
Results first posted
May 23, 2012
Last update
May 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01134705
Responsible party
Sponsor
First posted
Jun 2, 2010
Start date
May 2010
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
May 23, 2012
Last update
May 23, 2012

Study contacts

Sudeesh Tantry, Ph.D.
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion